Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of cancer"
DOI: 10.1016/j.ejca.2021.03.045
Abstract: BACKGROUND Neratinib is approved in the European Union for extended adjuvant treatment of human epidermal growth factor receptor 2-positive/hormone receptor-positive (copositive) early breast cancer ≤1 year of completion of prior trastuzumab-based therapy. Here, we report… read more here.
Keywords: early breast; copositive early; breast cancer; extended adjuvant ... See more keywords
Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-oncology practice"
DOI: 10.1093/nop/npac036
Abstract: Background This study was designed to compare outcomes of extended adjuvant temozolomide (TMZ) vs standard adjuvant TMZ following radiotherapy (RT) plus concurrent TMZ in newly diagnosed glioblastoma. Methods This systematic review and meta-analysis was carried… read more here.
Keywords: glioblastoma; adjuvant temozolomide; adjuvant tmz; extended adjuvant ... See more keywords
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials
Sign Up to like & getrecommendations! Published in 2023 at "BMJ Open"
DOI: 10.1136/bmjopen-2022-070972
Abstract: Introduction The type of extended adjuvant endocrine therapy is not clear, nor is the optimum duration of extended adjuvant endocrine therapy for patients with early breast cancer. Our study aims to satisfy the requirements for… read more here.
Keywords: meta analysis; breast cancer; endocrine therapy; network meta ... See more keywords
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-1131
Abstract: Purpose: The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater in… read more here.
Keywords: neratinib; her2 breast; adjuvant therapy; extended adjuvant ... See more keywords
Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1000501
Abstract: Objective To investigate whether extending adjuvant temozolomide (TMZ) improved the prognosis of newly diagnosed glioblastoma (GBM) patients with different mutation statuses of O6-methylguanine DNA methyltransferase (MGMT), isocitrate dehydrogenase 1 (IDH1), p53 and different expression level… read more here.
Keywords: newly diagnosed; adjuvant tmz; mutation; gbm ... See more keywords
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms232113604
Abstract: In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to… read more here.
Keywords: treatment luminal; luminal breast; breast; endocrine treatment ... See more keywords